Bringing IL-15 to Exhausted T Cells: A New Immunocytokine Enters Human Testing

For many cancer patients, the breakthroughs in immunotherapy are both real and limited. Checkpoint inhibitors can shrink or even eliminate some tumors, but they often run into the same wall: T cells that should be attacking cancer cells gradually become exhausted in the tumor microenvironment, like pressing the accelerator without enough power to move forward. How to reawaken these cells while avoiding a systemic immune storm is becoming the next round of competition in immuno-oncology.

SOT201, which SOTIO is testing clinically, is an immunocytokine designed for this problem. Company materials describe it as a PD-1-targeted, cis-acting attenuated IL-15 agonist: in other words, it aims to deliver IL-15 signaling as much as possible near CD8-positive T cells expressing PD-1, rather than allowing the cytokine to broadly activate immune cells throughout the body.

IL-15 itself is not a new target. It can promote activation of T cells and natural killer cells, so it has long been viewed as a candidate tool for anticancer immunotherapy. The problem is that if cytokines lack localization, they may bring fever, inflammation, and other toxicities. SOT201’s approach is to fuse attenuated human IL-15 and the IL-15Ralpha sushi domain to a humanized, Fc-silent anti-PD-1 antibody, using the antibody to carry the signal toward PD-1-positive T cells.

In the clinical trial design disclosed at the 2024 SITC meeting, VICTORIA-01 is a multicenter, open-label Phase 1 dose-escalation trial in adult patients with advanced or metastatic solid tumors who have no standard treatment options. The trial is expected to enroll about 40 people. SOT201 is administered by intravenous injection once every 21 days, and the main goals are to evaluate safety, tolerability, effective dose, highest administered dose or near-maximum tolerated dose, and to identify the recommended Phase 2 dose.

The company stated in the meeting materials that six clinical centers were participating at the time, located in the United States, Belgium, Spain, and the Czech Republic, and that four patients had already received treatment, with tolerability described as good. This is consistent with the direction emphasized in the latest reports: in patient testing, SOT201 appears able to stimulate exhausted T cells without triggering severe inflammation. However, the core purpose of this kind of early trial remains safety and dose exploration; the number of patients is extremely small, and efficacy or applicable cancer types cannot yet be inferred.

The main evidence supporting this strategy still comes from preclinical data. SOTIO’s poster indicated that SOT201 can deliver attenuated IL-15 signaling to PD-1-positive T cells in vitro and restore function in exhausted human T cells; in mouse tumor models, it also reported anti-tumor activity, partial complete responses, and a better effector T-cell profile compared with an anti-PD-1 antibody alone or non-PD-1-targeted IL-15 molecules. These results provide a biological rationale, but animal models and in vitro systems still differ substantially from human tumors.

The real weight of this research is not that it has already proven a new drug effective, but that it moves cytokine therapy from “powerfully stimulating immunity” toward more precise spatial control. If SOT201 can maintain safety in larger-scale trials and show a clear anti-tumor signal, it may open another path for patients with insufficient responses to checkpoint inhibitors. If it cannot avoid toxicity or insufficient efficacy, it will also remind researchers that exhausted T cells cannot necessarily return to the battlefield simply by receiving one more growth signal.